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This paper describes the studies performed with the candidate Certified Reference Material (CRM) of 
captopril, the first CRM of an active pharmaceutical ingredient (API) in Brazil, including determination 
of impurities (organic, inorganic and volatiles), homogeneity testing, short- and long-term stability 
studies, calculation of captopril content using the mass balance approach, and estimation of the associated 
measurement uncertainty.
Uniterms: Captopril/qualitative analysis. Medicines/Certified Reference Standards. Medicines/analytical 
quality control. High Pressure Liquid Chromatography (HPLC)/qualitative analysis. Medicines/
contamination.
Este artigo descreve os estudos realizados com o candidato a Material de Referência Certificado (MRC) 
de captopril, primeiro MRC de fármacos no Brasil, incluindo a determinação de impurezas (orgânicas, 
inorgânicas e voláteis), testes de homogeneidade, testes de estabilidade de curta e longa duração, cálculo do 
teor de captopril por balanço de massa e estimativa da incerteza de medição associada ao valor certificado.
Unitermos: Captopril/análise qualitativa. Fármacos/Padrões de Referência. Fármacos/controle analítico 
de qualidade. Cromatografia Líquida de Alta Eficiência/análise qualitativa. Medicamentos/contaminação.
INTRODUCTION
The use of Reference Materials (RM) is a common 
practice in the pharmaceutical area, both for qualitative 
and quantitative purposes, in order to comply with the 
pharmacopeial monographs. Nowadays, these pure subs-
tances, also called Reference Standards, can be easily 
purchased from different pharmacopeias.
An evaluation of RMs from a metrological point of 
view indicates that their use cannot provide traceability of 
measurement results to the International System of Units 
(SI). Metrological traceability is a requirement of the ISO 
17025 standard (ISO 17025:2005) and corresponds to “an 
unbroken chain of comparisons to stated references, usu-
ally national or international standards, all having stated 
uncertainties” (Duewer et al., 2004; ISO guide 30:1992; 
Eurachem/Citac, 2000; JCGM, 2008). In the absence of 
such standards, the Reference Materials can be traceable 
to physical or chemical properties (Duewer et al., 2004).
On the other hand, Certified Reference Materials 
(CRM) can provide measurement traceability and the-
refore they are correctly used to assign values to other 
materials, as well as for calibration, quality control and 
method validation (ISO guide 35:2006).
CRMs are high purity substances, stable, homoge-
neous, and fully characterized regarding their composi-
tion (Duewer et al., 2004), which are accompanied by a 
certificate or similar type of document declaring the spe-
cified value of a given property (the content of the active 
pharmaceutical ingredient, API, in case of pharmaceutical 
substances) and the associated measurement uncertainty 
(ISO guide 30:1992, ISO guide 30:1992/Amd. 1:2008, 
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ISO guide 35:2006; JCGM, 2008). The requirements for 
production and certification of Certified Reference Mate-
rials are set by the ISO guides 34:2009 and 35:2006 and 
include the characterization of the material, homogeneity 
testing, short- and long-term stability studies, as well as the 
estimation of the measurement uncertainty. For pharma-
copoeial standards, the ISO guide 35:2006 indicates that 
a different and specific approach may be used, provided 
the general principles of the guide are followed, while the 
ISO guide 34:2009 states that for most pharmacopoeial 
assay standards “the uncertainties of the assigned values 
are not stated, since they are considered to be negligible in 
relation to the defined limits of the method-specific assays 
for which they are used”.
The trueness of this last statement, which appears 
in the ISO guide 34 at least since its 2nd edition (2000), 
had previously come under question (Kuselman, Weis-
man, Wegscheider, 2003). Additionally, an international 
tendency to produce CRMs in the pharmaceutical area is 
evident, although their availability remains very limited. 
The United States Pharmacopeia (USP), for instance, 
whose Reference Standards have been available since 
1926 (Williams et al., 2006), developed its first CRM in 
September 2008: dextromethorphan hydrobromide. In the 
following year, three other CRMs were made available by 
the USP (teophylline, phenytoin and carbamazepine) (The 
United States Pharmacopeial Convention, 2010). Therefo-
re, increasing demand for Certified Reference Materials in 
the pharmaceutical area is likely, which in the near future 
may be increasingly provided by pharmacopeias or Na-
tional Metrology Institutes (NMIs).
In Brazil, although the National Health Surveillance 
Agency (Anvisa) still does not legally require the use of 
CRMs, the National Institute of Metrology, Normalization 
and Industrial Quality (Inmetro) started a pioneer project 
to develop the first Brazilian Certified Reference Material 
in the pharmaceutical area, and captopril CRM has been 
available on the market since April 2010. 
The mass balance approach has been chosen to 
determine captopril content, since this procedure was re-
ported to provide standard deviations up to 10 times lower 
compared to those obtained using the traditional assay 
methods for APIs (Hofer, Olsen, Rickard, 2007), thus 
leading to lower associated measurement uncertainties. 
This paper describes the studies performed with the 
candidate CRM of captopril, including quantification of 
the organic, inorganic and volatile impurities, evaluation 
of the between-bottle homogeneity, and of the short- and 
long-term stabilities, the use of the mass balance approach 
for calculation of captopril content, as well as estimation 
of associated measurement uncertainty.
MATERIALS AND METHODS
Instrumentation
A Shimadzu high performance liquid chromatogra-
ph (HPLC), equipped with quaternary pump LC-20AT, 
on-line degasser DGU-20A3/DGU-20A5, auto-sampler 
SIL-20A/20AC, photodiode array detector SPD-20A and 
interface CBM-20A/20A, was used for the determination 
of related substances. The data were processed using the 
software Lab Solution. The analysis conditions used were: 
mobile phase methanol - phosphoric acid 0.11% (55:45, 
v/v), flow - rate 1 mL/min, UV detection at 220 nm. The 
HPLC column was RP18, 25 cm x 4.6 mm i.d., 5 µm, 
Supelcosil (Supelco), to which a pre-column RP18, 4.6 
mm i.d., 5 µm (Varian) was attached. The same column 
was used for the LC-MS experiments, using a HPLC cou-
pled to a triple quadrupole (1200 L Quadrupole MS/MS, 
Varian), methanol - 10 mM formic acid (55:45, v/v) and 
methanol - 0.1% TFA (55:45, v/v) as mobile phases and 
0.2 mL/min as the flow-rate.
A Karl Fischer coulometer 831 Metrohm equipped 
with an oven sample processor 774 Metrohm and Tiamo 
1.2 software was used for water determination, using an 
oven temperature of 80 °C, extraction time of 300 s and 
nitrogen-flow of 115 mL/min. The Differential Scanning 
Calorimetry measurements were performed using a DSC 
Q1000 (TA Instruments) according to Moreira et al. 
(2010). For the gravimetric preparation of samples, an 
analytical Shimadzu balance, model AUW 220D, with 
resolution 0.01 mg was used. 
Samples and reagents
The studies were performed using samples of 
the first batch of Inmetro CRM of captopril (MRC 
09.1/09.001). Initially, the captopril was tested according 
to the F. Bras. IV ed. monograph and the results confirmed 
that it was a high purity material and suitable to become 
a candidate Certified Reference Material. The material 
was then packed in portions of 525 mg (nominal mass: 
500 mg, excess of 5%) in amber glass flasks, under con-
trolled temperature and humidity. The flasks were sealed 
with rubber caps and aluminum seals and identified with 
labels containing the CRM name and a serial number. 
Weight control was performed according to the F. Bras. 
IV ed. and the following results were obtained: average 
weight: 530.41 mg (n = 10), RSD 0.91%, greatest weight 
deviation from the average: 1.5%. All the tests described 
in this article were performed after the material had been 
packaged in its final form.
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USP Reference Standards of captopril (batch 
H 09120H, 100.0%) and of captopril disulfide (batch 
H0F251, 99.0%) were also analyzed by HPLC for com-
parison and were not dried before use.
For HPLC analysis, methanol HPLC grade (Tedia), 
o-phosphoric acid 85% w/w for analysis (Merck) and 
water type I were used. A Coulomat AG solution (Riedel-
deHaen) was used for Karl Fischer coulometric titration,
CRM characterization
The procedure chosen to determine the content of 
active pharmaceutical ingredients in the first Inmetro batch 
of captopril CRM was the mass balance approach (eq. 1). 
Captopril (%) = 100% - Σ organic impurities (%) -  
Σ inorganic impurities (%) - Σ volatiles (water and  
solvents) (%)   (eq. 1)
The organic impurities were determined by HPLC 
according to the related substances test in the F. Bras. IV 
ed. (2002) monograph. Solutions containing 500 µg/g and 
10 µg/g were prepared in triplicate from each CRM flask, 
and each solution was injected three times into the HPLC 
system. The HPLC method was validated and these studies 
revealed that the captopril was very unstable in solution, 
with formation of increasing amounts of its dimmer cap-
topril disulfide, as previously reported (Stulzer, Silva, 
2006). Therefore, the accurate quantification of organic 
impurities required the analysis of solutions immediately 
after their preparation. 
The content of each organic impurity in the captopril 
samples was determined according to eq. 2:
  (eq. 2)
where: [org] = content of each organic impurity in the 
captopril samples; Aimp = peak area of each organic impu-
rity (500 µg/g solution of captopril); Acapt dil = peak area 
of captopril (10 µg/g solution of captopril); DF = dilution 
factor from the 500 µg/g to the 10 µg/g solution; ΣAimp = 
sum of peak areas of all organic impurities
The inorganic impurities were determined using the 
residue of ignition test (ashing) according to the F. Bras. 
IV ed. Although more precise and sensitive methods are 
available to quantify inorganic metals, including AAS, 
ICP-AES, and ICP-MS, the determination of inorganic 
residues by ashing has previously been employed for the 
development of CRMs (Le Goff, Wood, 2009; Mathkar 
et al., 2009), since it is a gravimetric test which easily 
estimates the total content of inorganics in a sample. 
The volatiles were determined by the loss on drying 
(LOD) test, performed at 60 °C under vacuum for 3 hours, 
according to the F. Bras. IV ed. The results were compa-
red to the water content determined by coulometric Karl 
Fischer titration (oven method).
Homogeneity studies
The between-bottle variation was evaluated using 12 
CRM flasks selected at random. The HPLC analysis was 
done as previously described and the captopril content was 
determined by mass balance according to eq. 1.
Additionally, the homogeneity was also evaluated 
by oxidation-reduction titration with potentiometric end-
point, according to the assay method in the F. Bras. IV 
ed. monograph. This study used 24 samples, prepared in 
triplicate.
Short- and long-term stability studies
For the short-term stability study, 8 flasks of CRM, 
selected at random, were subjected simultaneously to a 
temperature of 50 °C. On pre-determined days, one flask 
was taken out of the oven and individually analyzed (clas-
sical design). Solutions containing 500 µg/g and 10 µg/g 
were prepared in triplicate from each CRM flask, and each 
solution was injected three times into the HPLC system. 
Three other CRM flasks, not exposed to the temperature 
of 50 °C, were analyzed (solutions prepared in triplicate, 
three injections per solution) and used as controls. The 
captopril content was calculated by mass balance.
For the long-term stability evaluation, the sam-
ples were kept at the recommended storage conditions 
(20-25 ºC). The analysis was performed four times 
throughout the year in which the certification study was 
performed (namely on the 1st, 11th, 30th and 38th weeks). 
At each timepoint, three flasks were analyzed in triplicate, 
whereby each solution was injected three times into the 
HPLC. After the 38th week, a monitoring program of the 
CRM samples was started. 
Estimation of measurement uncertainties
The uncertainty calculation was performed accor-
ding to the Eurachem/Citac guide (Eurachem/Citac, 2000). 
The relevant uncertainty sources are shown in the cause 
and effect diagram (Figure 1). Based on eq. 1, the uncer-
tainties due to the determination of organic impurities 
(uorg), of inorganic impurities (uinorg) and of volatiles (uvol) 
were included. Additionally, the between-bottle variation 
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uncertainty (ubb) and the long-term stability uncertainty 
(ults) were considered as uncertainty components. As ex-
plained later, the short-term stability uncertainty (usts) was 
not taken into account.
The uncertainty sources for the determination of 
organic impurities (uorg) were basically the parameters of 
eq. 2, as can be seen in Figure 1. The dilution factor (DF) 
covered the influence of the calibration of the analytical 
balance used for gravimetric preparation of samples, while 
the peak areas covered the influences of the HPLC system, 
the method, and of the captopril instability in solution. The 
combined uncertainty due to the determination of organic 
impurities (uorg), considering independent variables, was 
calculated according to eq. 3.
   (eq. 3)
where: δorg/δxi = sensitivity coefficient or partial diffe-
rential of content of organic impurities with respect to 
each uncertainty component xi; uxi = uncertainties due to 
components xi
The combined standard uncertainties (uc) due to 
the determination of inorganic impurities or to the de-
termination of volatiles (hereafter called uinorg and uvol, 
respectively) were calculated according to eq. 4, which 
took into account the uncertainty due to the repeatability 
(equation term containing the standard deviation, SD) and 
the uncertainty due to the analytical balance (equation term 
containing the expanded uncertainty U for the analytical 
balance).
   (eq. 4)
where: uc = combined standard uncertainty (%); SD = 
standard deviation; n = number of measurements; x = mean 
of results; U = expanded uncertainty for the analytical 
balance (mg); k = coverage factor (k = 2); m = average 
weighed mass (mg).
The uncertainty due to between-bottle (in)homo-
geneity (ubb) was calculated by eq. 5, according to ISO 
guide 35. 
  (eq. 5)
where: MSbetween = Mean square between groups (variation 
between units); MSwithin = Mean square within groups (va-
riation within the units); n = number of replicates.
The short-term stability uncertainty (usts) was calcu-
lated by eq. 6, which was also used to estimate the long-
term stability uncertainty (ults).
  (eq. 6)
where: usts = uncertainty due to short-term stability; s(b1) = 
uncertainty of the slope (equivalent to standard error in b1 
in regression analysis); t = time.
Finally, the combined standard uncertainty associa-
ted with the CRM property value (uCRM) was calculated 
FIGURE 1 - Cause and effect diagram.
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according to the law of propagation of uncertainties, which 
consists of “the square root of the total variance obtained 
by combining all the uncertainty components” (Eurachem/
Citac, 2000) (eq. 7), considered to be independent varia-
bles and expressed in the same unit. 
  (eq. 7)
The expanded uncertainty (U), which is “the interval 
within which the value of the measurand is believed to lie 
with a higher level of confidence” (Eurachem/Citac, 2000) 
was calculated according to eq. 8.
   (eq. 8)
where: k = coverage factor (k = 2 for a 95% confidence 
level; ABNT/Inmetro, 2003).
RESULTS AND DISCUSSION
The certification steps after material evaluation and 
packaging, were as follows:
1. CRM characterization:
1.1. Determination of organic impurities;
1.2. Determination of inorganic impurities;
1.3. Determination of volatiles.
2. Homogeneity studies;
3. Short-term stability studies;
4. Long-term stability studies;
5. Mass balance.
In all steps, the associated measurement uncertain-
ties were estimated. 
Captopril CRM characterization
Determination of organic impurities
The quantification of the related substances of 
captopril according to eq. 2 has been chosen based on 
the following aspects: a) it is not an assay calculation 
and therefore does not rely on the use of the Certified 
Reference Materials of captopril and captopril disulfide, 
which are not available and could not be used to guaran-
tee traceability; b) the single factor analysis of variance 
(Anova) of the normalized mean peak areas of seven 
individual solutions containing 10 µg/g of captopril USP 
reference standard or 10 µg/g of captopril disulfide USP 
reference standard, prepared on different days and in-
jected six times each, indicated no significant difference 
between the two groups (captopril and disulfide), since 
F value 2.3105 < F crit 4.7472; and c) the peak area of 
captopril and impurities are of the same order of magni-
tude, since the peak area of captopril is obtained from the 
10 µg/g solution and corrected by the dilution factor (DF).
The content of related substances determined by 
HPLC was 0.313264%, of which 0.259449% (ca. 82%) 
was represented by the main impurity captopril disulfide. 
These results were in accordance with the F. Bras. IV 
ed. acceptance criteria for captopril (maximum of 1.0% 
captopril disulfide and 2.0% total organic impurities) and 
were confirmed by three further measurements performed 
using the same procedure, as described later in the long-
term stability studies. The combined uncertainty due to 
the determination of related substances (uorg) calculated 
according to eq. 3 was 0.036149%.
Additionally, captopril was also analyzed by high 
performance liquid chromatography coupled to mass 
spectrometry (LC-MS), in order to identify the unknown 
impurities observed by HPLC-DAD, eluted before the 
captopril peak and also between the peaks of captopril 
and disulfide (Figure 2), although their contents were 
below 0.05%, which is the lowest threshold proposed by 
the ICH for the identification of unknowns (ICH, 1994). 
The MS detection considered the molecular weights of 
the captopril impurities described in the literature (LGC, 
2010). The following signals could be clearly identified: 
[M + H]+ 218: captopril, [M + H]+ 433: captopril disulfide, 
[M + H]+ 70 and 116: captopril fragments. Concerning the 
impurities, despite using the 0.1% formic acid containing-
phase, which resulted in stronger MS response compared 
to the 0.1% TFA phase, it was still not possible to identify 
the unknown impurities of captopril. 
Determination of inorganic impurities
The content of inorganic impurities determined 
by the residue of ignition test was 0.02398% (n = 9) 
(Table I), which is in accordance with the specified limit 
of 0.2% in the F. Bras. IV ed. monograph of captopril. 
The calculated value of uinorg (eq. 4) was 0.002976% 
(considering m = 973.089 mg, U = 0.06 mg and k = 2).
Determination of volatiles
The content of volatiles in the captopril CRM deter-
mined by the loss on drying (LOD) test was 0.097744% 
(n = 10), as shown in Table II, which is in accordance 
with the specified limit of 1.0% for the loss on drying test 
described in the F. Bras. IV ed. monograph of captopril. 
The uncertainty (uvol) estimated by eq. 4 was 0.004889% 
(considering m = 501.3 mg, U = 0.06 mg and k = 2).
The water content determined by Karl Fischer coulo-
metric titration was 0.025183% (n = 10, u = 0.000800%), 
a lower value compared to the result of the loss on drying 
(LOD) test. This difference may be explained by the fact 
R. Nogueira, E. C. P. Rego, M. V. B. Sousa, W. Wollinger, T. E. Silva, G. F. Moreira, J. S. Barin, L. V. Laporta et al.344
FIGURE 2 - HPLC-DAD chromatogram for captopril CRM (related substances test) (a) and enlargement (b). Experimental 
conditions: mobile phase methanol - phosphoric acid 0.11% (55:45, v/v), flow-rate 1 ml/min, UV detection at 220 nm, HPLC 
column RP18, 5 µm, 25 cm x 4.6 mm i.d.; pre-column RP18, 5 µm, 4.6 mm i.d.
TABLE I - Results for the residue of ignition test
Weighed mass (g) Results (%)
1 0.9306 0.03224
2 0.9449 0.01058
3 0.9799 0.03062
4 0.9675 0.02067
5 0.9705 0.03091
6 0.9953 0.02009
7 0.9869 0.03040
8 0.9886 0.01012
9 0.9936 0.03019
Average (x) 0.023980
SD 0.00893
RSD (%) 37.23
N 9
TABLE II - Results for loss on drying test
Weighed mass (g) Results (%)
1 0.5023 0.09944
2 0.5009 0.07979
3 0.5014 0.07971
4 0.5182 0.09639
5 0.5001 0.09988
6 0.5047 0.09897
7 0.4999 0.11988
8 0.4838 0.12386
9 0.5016 0.09958
10 0.5001 0.07992
Average (x) 0.097744
SD 0.01546
RSD (%) 15.82
N 10
that the Karl Fischer method is insensitive to residual sol-
vents, therefore the results obtained by the Karl Fischer 
and the loss on drying tests may not be comparable (Smith, 
Webb, 2007).
Homogeneity studies
The captopril contents of the samples for homoge-
neity evaluation were calculated by mass balance (eq. 1) 
and the results are shown in Table III. Considering the 
instability of captopril in solution according to the method 
validation studies, the sample solutions were injected into 
the HPLC system just after preparation, and therefore the 
randomized order of analysis recommended by the ISO 
guide 35:2006 could not be used. However, no trends were 
observed in the results related to the order of injection of 
samples (Figure 3a) or to the flask number (Figure 3b), 
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which was designated sequentially during the packaging 
operation of the CRM.
The single-factor analysis of variance of the capto-
pril contents resulted in a mean square between groups 
(MSbetween) of 0.000981 and a mean square within groups 
(MSwithin) of 0.000287. Using eq. 5, the uncertainty due to 
between-bottle (in)homogeneity (ubb) was estimated to be 
0.015218%. 
The homogeneity of captopril CRM was also evalu-
ated by oxidation-reduction titration (F. Bras. IV ed.) and 
resulted in an average value of 100.04 (n = 24, samples 
prepared in triplicate), with RSD 0.32%. The results lar-
ger than 100% may be explained by the variability of the 
titrimetric methods (an expanded uncertainty of 1% has 
been estimated for the titration assay of another analyte, 
as reported by Rodomonte, Montinaro, Bartolomei, 2006), 
and possibly also by the non-specificity of this technique, 
since the organic impurities usually contain moieties of 
similar reactivity to that of the analyte (Duewer et al., 
2004; Gorog, 2005).
In the literature, at least eight different impurities are 
described for captopril (LGC, 2010), namely Imp. A (cap-
topril disulfide), Imp. C ((2RS)-2-methyl-3-sulphanylpro-
panoic acid), Imp. D ((2RS)-3-bromo-2-methylpropanoic 
acid), Imp. E ((2S)-1-[2-methylpropanoyl]-pyrrolidine-2-
carboxylic acid), Imp. J (S-acetylcaptopril hydrate), Imp. 
K ((2S)-3-(acetylthio)-2-methylpropanoic acid), Imp. N 
((2S,2’S)-3,3’-disulphane-diylbis(2-methylpropanoic) 
acid) and captopril ethyl ester. Of these impurities, two 
contain a sulphydryl group (Imp. C and captopril ethyl 
FIGURE 3 - Results for the homogeneity study: captopril 
contents in twelve samples analyzed in triplicate and ordered 
from left to the right according to: (a) the HPLC injection order; 
and (b) the packaging order (serial numbers).
TABLE III - Homogeneity results
Sample nr.
Replicate 1 
(%)
Replicate 2 
(%)
Replicate 3 
(%)
Average 
(%)
SD 
(%)
n
1 16 99.57 99.58 99.57 99.57 0.0013 3
2 180 99.57 99.57 99.54 99.56 0.0191 3
3 446 99.59 99.52 99.58 99.56 0.0351 3
4 76 99.59 99.55 99.53 99.56 0.0310 3
5 264 99.59 99.59 99.59 99.59 0.0014 3
6 416 99.59 99.57 99.56 99.57 0.0165 3
7 61 99.60 99.59 99.58 99.59 0.0090 3
8 286 99.60 99.60 99.59 99.60 0.0054 3
9 438  (1) 99.61 99.61 99.61 0.0023 2
10 11 99.55 99.56 (1) 99.55 0.0060 2
11 318 99.55 99.57 99.55 99.56 0.0132 3
12 468 99.56 99.56 99.56 99.56 0.0035 3
Average: 99.57
(1) Error in the HPLC injection
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ester), akin to the captopril, and therefore may possibly 
react with the titrant. 
Notwithstanding, the titration results were useful to 
confirm the between-bottle homogeneity of captopril CRM 
(F value 0.9542 < F crit 1.7568 on single factor analysis 
of variance). For purposes of comparison, the titration 
resulted in a larger ubb value (0.083836%) compared to the 
HPLC analysis / mass balance determination.
Short-term stability studies
Short-term stability studies were performed to eva-
luate the stability of the captopril CRM under conditions 
which the material may be submitted to during transport. 
The study was carried out using the classical design (ISO 
guide 35:2006), that is, under reproducibility conditions: 
all flasks were subjected to 50 ºC at the same time, and then 
analyzed individually on pre-determined days. This type 
of study is expected to result in larger uncertainty values, 
because possible variations in the measurement system, 
in this case HPLC, are also included.
The reason for not using the isochronous design, 
which is performed under repeatability conditions (all 
samples analyzed in the same series) and results in smaller 
uncertainties and therefore is the preferred approach accor-
ding to the ISO guide 35:2006, was based on the validation 
studies. It was observed that captopril in solution suffers 
degradation, with formation of increasing amounts of its 
dimmer, captopril disulfide. Therefore, it would not be 
reasonable to analyze all the samples in a single set.
The captopril contents in the short-term stability 
samples, calculated according to eq. 1, are shown in Fi-
gure 4, while Table IV shows the regression analysis. The 
F value less than F critical (or the p-value greater than 
0.05) confirmed the stability of the captopril CRM under 
transport conditions (50 ºC, 12 days).
The short-term stability uncertainty (usts) (eq. 6) was 
0.005544%, considering a time period of 12 days. Since 
this value is smaller than the long-term stability uncertain-
ty (see following paragraph), it was not taken into account 
for the calculation of the measurement uncertainty of the 
certified value of the captopril CRM, as allowed by the 
ISO guide 35:2006.
Long-term stability studies
The long-term stability studies were carried out to 
evaluate the stability of the CRM material under storage 
conditions. Table V shows the contents of related substan-
ces determined by eq. 2 and also by assay using the USP 
standards of captopril disulfide and of captopril (in the 
case of unknown impurities), following the recommen-
dation to compare the CRM results with those obtained 
using (certified) reference materials (ISO guide 34:2009; 
Eurachem/Citac, 2000). As depicted in Table V, the two 
average contents did not differ significantly.
The captopril contents determined by mass balance 
(eq. 1) in the long-term stability study are shown in Figure 
5, while the corresponding regression analysis can be seen 
in Table VI. The F value less than F critical (or the p-value 
greater than 0.05) confirmed the stability of the captopril 
CRM under storage conditions (25 °C, 38 weeks). 
The uncertainty associated with the long-term 
stability (ults) was calculated by eq. 6 and the value of 
FIGURE 4 - Results for short-term stability study.
TABLE IV - Regression analysis for short-term stability results
Source Df SS MS F p-value F critical *
Regression 1 0.001040771 0.00104077 3.065347797 0.083139509 3.9391
Residual 97 0.032934211 0.00033953
Total 98 0.033974982
Coefficients Standard error Stat t p-value Lower 95% Upper 95%
Intercept 99.57428 0.002800007 35562.1577 0 99.56872003 99.5798345
Variable x 1 -0.000809 0.000462024 -1.7508135 0.083139509 -0.00172591 0.000108072
* F crit =INVF(0.05;1;df(residual))
Development studies of captopril certified reference material 347
0.024173% was estimated considering the time “t” as the 
shelf life of 156 weeks (3 years) for the captopril CRM. 
CRM certified value and measurement 
uncertainty
The certified value of the captopril CRM was de-
termined by mass balance (eq. 1), using the contents of 
organic impurities (related substances by HPLC), inorga-
nic impurities (residue on ignition test) and volatiles (loss 
on drying test), as described in the previous paragraphs. 
As shown in Table VII, the certified property value was 
99.565% in mass fraction, the combined standard uncer-
FIGURE 5 - Results for long-term stability study.
TABLE V - Related substances results for long-term stability evaluation
Test nr. Week
Related substances (%)
Peak area ratio (eq. 2) Assay using USP standards
1 1 0.313264 0.389631
2 11 0.306145 0.285779
3 30 0.278250 0.256969
4 38 0.321211 0.298205
Average 0.3047 0.3076
SD 0.0187 0.0573
RSD (%) 6.13 18.63
tainty associated with the CRM property value (uCRM) (eq. 
7) was 0.046414%, and expanded uncertainty (U), using 
a value of 2 as the coverage factor for a confidence level 
of approximately 95% (eq. 8), was 0.093%.
The magnitude of the different uncertainty contri-
butions to the value of uCRM are shown diagrammatically 
in Figure 6. The largest contributions came from the 
determination of organic impurities (uorg) and from the 
long-term stability studies (ults), followed by homogeneity 
uncertainty (ubb). The uncertainties due to the determina-
tion of inorganic impurities (uinorg) and volatiles (uvol) were 
less significant.
The certified value was confirmed by Differential 
Scanning Calorimetry (DSC), according to the recommen-
dation for use of one primary method or two independent 
secondary methods for certification (ISO guide 35:2006). 
The DSC can be considered a primary direct method, since 
it does not rely on the use of a “measurement standard for 
a quantity of the same kind” (JCGM, 2008), although em-
pirical corrections may be necessary in practice (Duewer 
et al., 2004).
The methodology for purity determination by DSC 
is described by the ASTM Standard E 928-08 (“Standard 
Test Method for Purity by Differential Scanning Calorime-
try”). This method is based on the Van’t Hoff law and its 
derived equation (eq. 9), according to which the presence 
of impurities leads to the depreciation of the melting point 
TABLE VI - Regression analysis for long-term stability results
Source Df SS MS F p-value F critical *
Regression 1 0.00070209 0.00070209 1.326613296 0.52154865 3.9361
Residual 100 0.052923465 0.00052923
Total 101 0.053625555
Coefficients Standard error Stat t p-value Lower 95% Upper 95%
Intercept 99.569813 0.003744131 26593.5715 0 99.56238447 99.57724097
Variable x 1 0.0001785 0.000154957 1.151787 0.252154865 -0.000128953 0.000485907
* F crit =INVF(0.05;1;df(residual))
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(ASTM, 2008). It represents an accurate, fast and conve-
nient method for substances with purity higher than 98.5%.
   (eq. 9)
where: TS = actual melting temperature; T0 = melting tem-
perature of pure compound; R = gas constant; c = mole 
fraction of impurity; DH = heat of fusion of pure com-
pound; F = fraction of molten material, determined by 
measuring partial areas of fusion peak observed in DSC
Eq. 9 can be considered a first degree equation 
(y = ax + b), in which y = TS; a = -R(T0)
2c/DH; x = 1/F; 
b = T0. Normally the graph from TS versus 1/F does not 
exhibit strict linear behaviour. The linearization is accom-
plished by adding an arbitrary area (c) to the total peak area 
(Atot) and to each partial area (Apart), as shown in eq. 10.
  (eq. 10)
The ASTM standard E 928-03 provides two metho-
ds for purity calculation according to the Van’t Hoff law 
equation. For “method A” used in this study, the software 
TA Universal Analysis 2000 (TA Instruments) was em-
ployed for the calculations. The value of c is determined 
using the nonlinear least squares technique and then used 
for the linearization of the curve TS versus 1/F. The linear 
and angular coefficients are estimated by linear regression. 
Finally, the mole fraction of impurities in each sample is 
determined from the angular coefficient.
Figure 7 shows the DSC curve obtained for captopril 
CRM. During captopril heating, a well-defined and sym-
metric endothermic peak was observed, which is typical of 
a constant temperature melting transition. In addition, the 
baseline was maintained, suggesting that the heat capacity 
of the material does not change during the process. Fur-
thermore, there was no other phase transition during the 
DSC scan. Therefore, the material presented ideal condi-
tions for purity calculation by the ASTM standard method.
The captopril content determined by DSC was 99.65 
± 0.023 % mol/mol, demonstrating that the purity of 
analytes with a known impurity profile, such as captopril 
CRM, can be determined equivalently by DSC and HPLC 
(Moreira et al., 2010). Another study also indicated that 
the purity obtained by DSC is comparable to the purity 
determined by HPLC in case of organic compounds with 
at least 98% purity (Mathkar et al., 2009).
The captopril content of the CRM determined by 
titration, according to the assay procedure described in 
the F. Bras. IV. ed., was greater than 100% (100.04% + 
0.32%). Therefore, although the use of titration, a primary 
direct method (Duewer et al., 2004; Gorog, 2005; ISO gui-
de 35:2006), would be more recommended to determine 
the property value of captopril CRM, it proved to be less 
indicated for certification compared to the mass balance 
approach.
FIGURE 6 - Uncertainty contributions.
TABLE VII - Captopril content in Certified Reference Material and associated measurement uncertainty
% u (%) U (%) *
Initial 100.000000
Related substances (organic 
impurities)
0.313264 0.036149
Inorganic impurities 0.023980 0.002976
Volatiles 0.097774 0.004889
Long-term stability 0.024173
Homogeneity 0.015181
Average 99.564982 0.046414 0.092829
* Considering a coverage factor of 2
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FIGURE 7 - DSC curve for captopril CRM in the 100-115 °C range (heating rate of 0.5 ºC/min) and inert atmosphere (He, 
50 mL/min). Curves and values generated by the software TA Universal Analysis 2000 for calculation in purity determination.
CONCLUSIONS
The candidate Certified Reference Material (CRM) 
of captopril, the first Inmetro batch, has been certified. The 
certified reference value and expanded uncertainty (U), 
using the value of 2 as the coverage factor for a confiden-
ce level of approximately 95%, was 99.565 ± 0.093% in 
mass fraction. 
Captopril CRM is the first Brazilian Certified Re-
ference Material in the pharmaceutical area and allows 
analytical laboratories and research institutes to obtain 
traceable measurements, in compliance with the ISO 
17025:2005 requirements.
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